▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2538 by analyst upside · 2026-08-12
CTKB
Cytek Biosciences, Inc.
Healthcare · Market Cap $616M · P/E 0x
ANALYST PRICE TARGET
+17.4%
implied upside to consensus target
Current Price $4.74
Consensus Target $5.56
Bull Target $7.5
Bear Target $4.75
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
1
Hold
2
Sell
0
52-Week Low $3.28
52-Week High $6.18
YTD Return -3.7%
FUNDAMENTALS
Market Cap $616M
P/E Ratio (TTM) N/A
Forward P/E 67.7x
EPS (TTM) $-0.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $207M
Profit Margin -39.0%
52-WEEK RANGE
52-Week Low $3.28
52-Week High $6.18
Current Price $4.74
Bear Target $4.75
Bull Target $7.5
● Now $4.74 ● Target $5.56
TRADING DATA
Avg Volume 1.4M
YTD Return -3.7%
Analyst Count 4
Consensus Buy
Upside to Target +17.4%
Last Updated 2026-08-12

ANALYST SUMMARY

Cytek Biosciences, Inc. (CTKB) is currently trading at $4.74 with a Wall Street consensus price target of $5.56, implying potential upside of 17.4% over the next 12 months. 4 analysts currently cover CTKB, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $7.5, while the most cautious has a target of $4.75.

CTKB operates in the Healthcare sector with a market capitalisation of $616M. The stock is down 3.7% year-to-date and is currently trading near the upper end of its 52-week range of $3.28 – $6.18.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RIGL +32.3%
Rigel Pharmaceuticals, Inc.
$785M · P/E 2.5x · Buy
IRWD +41.9%
Ironwood Pharmaceuticals, Inc.
$711M · P/E 5.4x · Buy
TBPH +4.4%
Theravance Biopharma, Inc.
$878M · P/E 7.6x · Hold
AMPH +7.7%
Amphastar Pharmaceuticals, Inc.
$869M · P/E 12.1x · Hold
ABUS +18.8%
Arbutus Biopharma Corporation
$923M · P/E 5.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CTKB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Stephens & Co. - Reiterated
Overweight → Overweight 2026-05-13 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-01-08 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2025-11-11 14% win rate (7 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2025-05-28 Building track record
Goldman Sachs - Reiterated
Sell → Sell 2025-05-12 Building track record
Stephens & Co. reit
Overweight → Overweight 2025-03-19 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2025-03-04 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
12/30
Consensus clarity
18/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →